Globus Medical Inc (GMED) Shares Reduced by Tudor Investment Corp Et Al

Globus Medical Inc (GMED) Shares Reduced by Tudor Investment Corp Et Al

Tudor Investment Corp Et Al reduced its stake in Globus Medical Inc (NYSE:GMED) by 86.7% during the fourth quarter, Holdings Channel reports. The firm owned 11,200 shares of the medical device company’s stock after selling 72,893 shares during the period. Tudor Investment Corp Et Al’s holdings in Globus Medical were worth $278,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in Globus Medical by 0.7% in the third quarter. Rhumbline Advisers now owns 74,078 shares of the medical device company’s stock worth $1,672,000 after buying an additional 515 shares during the last quarter. 1st Global Advisors Inc. boosted its position in Globus Medical by 8.2% in the third quarter. 1st Global Advisors Inc. now owns 10,780 shares of the medical device company’s stock worth $243,000 after buying an additional 818 shares during the last quarter. Acrospire Investment Management LLC boosted its position in Globus Medical by 31.7% in the third quarter. Acrospire Investment Management LLC now owns 5,400 shares of the medical device company’s stock worth $122,000 after buying an additional 1,300 shares during the last quarter. California State Teachers Retirement System boosted its position in Globus Medical by 1.0% in the third quarter. California State Teachers Retirement System now owns 148,336 shares of the medical device company’s stock worth $3,348,000 after buying an additional 1,400 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in Globus Medical by 13.3% in the third quarter. Alps Advisors Inc. now owns 18,272 shares of the medical device company’s stock worth $412,000 after buying an additional 2,144 shares during the last quarter. Institutional investors and hedge funds own 88.55% of the company’s stock.

Globus Medical Inc (NYSE:GMED) opened at 29.31 on Wednesday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of 27.14 and a beta of 0.63. The company’s 50-day moving average price is $27.49 and its 200-day moving average price is $24.42. Globus Medical Inc has a 52-week low of $19.25 and a 52-week high of $29.70.

Globus Medical (NYSE:GMED) last released its earnings results on Monday, February 27th. The medical device company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by $0.02. The business had revenue of $151.59 million for the quarter, compared to the consensus estimate of $149.30 million. Globus Medical had a net margin of 21.20% and a return on equity of 14.92%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.39 EPS. Equities research analysts expect that Globus Medical Inc will post $1.27 EPS for the current fiscal year.

A number of research firms have recently commented on GMED. Oppenheimer Holdings Inc. set a $29.00 target price on Globus Medical and gave the company a “hold” rating in a research note on Tuesday, February 28th. Aegis restated a “buy” rating and issued a $31.00 target price on shares of Globus Medical in a research note on Tuesday, February 28th. Canaccord Genuity restated a “hold” rating and issued a $27.00 target price on shares of Globus Medical in a research note on Monday, January 23rd. Finally, Zacks Investment Research upgraded Globus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. Globus Medical presently has a consensus rating of “Hold” and an average price target of $25.60.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).

Related posts

Leave a Comment